ABEO Stock — Abeona Therapeutics Inc.: Cash, EV, Pipeline

What they do

The Company’s development portfolio also features adeno-associated virus (“AAV”)-based gene therapies designed to treat ophthalmic diseases with high unmet need using novel AIM™ capsids. Abeona’s novel AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Source: 10-K FY2025 via SEC EDGAR

Share price

$4.17

Market cap

$238.5M

Cash

$146.8M

Enterprise value

$93.3M

Balance sheet

Cash	$146.8M
Debt	$1.7M
Net cash	$145.2M
Enterprise value	$93.3M
Basic shares	57.2M shares
Fully diluted shares	75.7M shares
Fully diluted market cap	$315.6M
Cash per share	$2.57
Quarterly burn	$17.5M
Cash runway	8.4 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

57.2M

Pre-funded warrants

4.9M

Options

0.0M

RSUs

4.7M

Warrants

8.2M

Converts

0.6M

Conv preferred

0.0M

ESPP reserve

—

FDSO

75.7M

Cap table as of 2026-06-30.

Price history

Loading ABEO daily closes…

Loading price history…

Next catalyst

UX111 · Apr 12 - May 24 in 30 mo · Phase 3 · MPS IIIA; Sanfilippo Syndrome; Sanfilippo A

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 12 - May 24 in 30 mo	UX111	Phase 3	MPS IIIA; Sanfilippo Syndrome; Sanfilippo A	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ZEVASKYN (prademagene zamikeracel)

Approved · Active Modality: autologous gene-modified cellular sheets (gene-modified epidermal sheets)

Target COL7A1

Indications

Recessive dystrophic epidermolysis bullosa (RDEB) wounds (Approved)

Status note FDA approved April 28, 2025; described as the first and only autologous cell-based gene therapy for RDEB wounds.

ABO-701

Preclinical · Active Modality: engineered T-cell therapy (synthetic immune receptor SIR-T)

Target PSMA

Partnerships Reverence Enterprises, LLC: $7.0M upfront; up to $1.0M event-based milestones

Indications

Prostate cancer (Stage not disclosed)

Status note 10-Q calls ABO-701 a recently licensed engineered T-cell therapy targeting PSMA for prostate cancer and separately describes the March 18, 2026 Reverence license for the PSMA SIR-T autologous T-cell product (IND to be filed, Phase 1 study planned); the filing does not state ABO-701 and the SIR-T product are the same candidate. Indication stage pending IND.

ABO-503

Preclinical · Active Modality: AAV gene therapy (RS1 packaged in AAV204 AIM capsid)

Target RS1

Indications

X-linked retinoschisis (XLRS) (Stage not disclosed)

Status note Deprioritized per Q2 2026 10-Q (soft wind-down, not discontinued). 10-K: pre-IND meeting April 2023; animal efficacy/toxicology and cGMP manufacturing postponed to 2026. Beacon Therapeutics out-licenses the AAV204 capsid for select ophthalmology targets (upfront + milestones + tiered royalties).

ABO-504

Preclinical · Active Modality: dual AAV vector gene therapy (Cre-LoxP recombinase system reconstituting full-length ABCA4)

Target ABCA4

Indications

Stargardt disease (Stage not disclosed)

Status note Deprioritized per Q2 2026 10-Q (soft wind-down, not discontinued). 10-K: pre-IND meeting June 2023.

ABO-505

Preclinical · Active Modality: AAV gene therapy (Opa1 delivered via AAV204)

Target Opa1

Indications

Autosomal dominant optic atrophy (ADOA) (Stage not disclosed)

Status note Deprioritized per Q2 2026 10-Q (soft wind-down, not discontinued). Para-retinal injection; preclinical only per 10-K.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Non-conforming pz-cel surgical application to RDEB wounds
Lead indication	Epidermolysis Bullosa (EB)
Lead phase	Phase 4
Active trials	4
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05725018	Phase 3	Active, not recruiting	Sponsor	ABEO	—	Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; RDEB	—
NCT07717736	Not disclosed	Not yet recruiting	Sponsor	ABEO	—	Epidermolysis Bullosa (EB); Recessive Dystrophic Epidermolysis Bullosa (RDEB); Dystrophic Epidermolysis Bullosa (DEB)	—
NCT05708677	Not disclosed	Enrolling by invitation	Sponsor	ABEO	—	RDEB	—
NCT07700966	Not disclosed	Recruiting	Sponsor	ABEO	—	Recessive Dystrophic Epidermolysis Bullosa	—
NCT02716246	Phase 3	Recruiting	Collaborator	RARE	—	MPS IIIA; Sanfilippo Syndrome; Sanfilippo A	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Abeona Therapeutics, Inc on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Stonepine Capital	557,284	-189,303	2.62%	2026-08-17
Tang Capital Partners	0	-400,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ABEO — Abeona Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ABEO — Abeona Therapeutics Inc.